Breaking News: Regeneron Pharmaceuticals Securities Fraud Class Action Lawsuit
On March 6, 2025, Glancy Prongay & Murray LLP announced that investors who have suffered losses on their Regeneron Pharmaceuticals, Inc. (Regeneron or the Company) investments have the opportunity to lead the securities fraud class action lawsuit against the biotech company. The lawsuit alleges that Regeneron and certain of its executives made false and misleading statements and failed to disclose material information to the investing public.
Background on Regeneron Pharmaceuticals
Regeneron is a leading biotechnology company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Its most well-known drugs include Eylea, Dupixent, and Libtayo. The company’s stock has performed well in recent years, with its share price more than tripling from 2015 to 2025.
The Allegations
The securities fraud class action lawsuit alleges that Regeneron and certain executives made false and misleading statements regarding the safety and efficacy of its drug, Evkeeza, which is used to treat certain blood disorders. The lawsuit claims that Regeneron downplayed the risks associated with Evkeeza and inflated the drug’s potential benefits.
Impact on Investors
The lawsuit could have significant implications for Regeneron investors who purchased the company’s stock between certain dates. If the allegations are proven true, these investors may be entitled to damages. The lead plaintiff deadline for joining the class action lawsuit is March 10, 2025.
Impact on the Biotech Industry
The Regeneron securities fraud class action lawsuit could set a precedent for other biotech companies and their executives. It highlights the importance of transparency and accurate reporting in the industry. The outcome of the lawsuit could also impact investor confidence in biotech stocks and potentially lead to increased regulatory scrutiny.
Conclusion
Investors who have suffered losses on their Regeneron Pharmaceuticals investments due to alleged securities fraud have the opportunity to lead a class action lawsuit against the company. The lawsuit alleges that Regeneron and certain executives made false and misleading statements regarding the safety and efficacy of its drug, Evkeeza. The impact of the lawsuit could be significant for Regeneron investors and the biotech industry as a whole. If you believe you may be eligible to join the class action lawsuit, contact Glancy Prongay & Murray LLP before the lead plaintiff deadline on March 10, 2025.
- Regeneron Pharmaceuticals, Inc. is a leading biotech company that discovered, invented, developed, manufactured, and commercialized medicines for serious medical conditions.
- The company’s stock has performed well in recent years, with its share price more than tripling from 2015 to 2025.
- The securities fraud class action lawsuit alleges that Regeneron and certain executives made false and misleading statements regarding the safety and efficacy of its drug, Evkeeza.
- The lawsuit could have significant implications for Regeneron investors who purchased the company’s stock between certain dates.
- The impact of the lawsuit could also impact investor confidence in biotech stocks and potentially lead to increased regulatory scrutiny.
